These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2014-003071-37 Multicenter, randomized, double-blind, two-period, placebo controlled, forced-titration proof of concept crossover study to compare QGC001 with placebo in patients with grade I or II essential hyperte... 2016-04-13 due-trials
Listed as ongoing, but also has a completion date 2015-005607-92 A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients upon discharge from hospital admission for worsenin... 2018-10-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-003146-17 A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventric... 2021-07-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2019-004509-29 A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects 2022-09-20 bad-data
Listed as ongoing, but also has a completion date 2021-001404-14 A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-... 2023-01-09 bad-data